Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2002

View Archived Issues

Factor 5A gene is expressed in human heart tissue

Potential use of alefacept in scleroderma lung disease

Improved prevention of chemotherapy-induced nausea and vomiting reported for aprepitant

New assessment of palonosetron for CINV

Novel MC1 and/or MC4 receptor modulators in BMS pipeline

Telik and Sanwa describe new MCP-1 antagonists with potential in asthma and other disorders

Antibacterial compounds in early development at Daiichi

Sankyo prepares and tests new ACAT inhibitors

Novel PARP inhibitors and their use in inflammatory disorders reported by Yamanouchi

Series of SGLT-2 inhibitors designed by Kissei

Bayer researchers present novel activators of guanylate cyclase

InterLink Biotechnologies and Genome Therapeutics collaborate on antiinfective drug discovery

Third safety study for OxyTrex initiated

Genasense in combination with Rituxan evaluated in NHL patients

Promising laboratory results for phosphate-lowering RenaZorb

Orphan drug designation awarded to Neovastat in renal cell carcinoma

Celgene signs to promote Gelclair to U.S. oncology market

Largest ADHD study supports Adderall XR for improvement of symptoms and quality of life

TAP Pharmaceutical submits NDA for Uprima for ED

Effects of Enteryx on LES function in GERD patients

Rectal administration of PL-14736 safe in first human study

YH-1885 for one week significantly inhibits intragastric acidity in humans

Beneficial effects of Z-338 in patients with functional dyspepsia

Antiproliferative activity of triptolide characterized against human prostatic epithelial cells

Organ Recovery Systems cleared to market improved kidney perfusion solution

Sales of WorldHeart's Novacor LVAS continue to rise

LF-15-0195 induces long-term heart allograft survival in rat model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...